Table I.
Association of ZEB1 expression in ovarian carcinoma with clinicopathological characteristics.
| ZEB1 expression in tumor cells by IHC | ||||
|---|---|---|---|---|
| Characteristics | Total (n=238) | Negative, n (%) (n=160) | Positive, n (%) (n=78) | P-value |
| Age (years) | 0.423 | |||
| ≤39 | 16 | 9 (56.2) | 7 (43.8) | |
| 40–49 | 38 | 26 (68.4) | 12 (31.6) | |
| 50–59 | 61 | 40 (65.6) | 21 (34.4) | |
| 60–69 | 69 | 46 (66.7) | 23 (33.3) | |
| ≥70 | 39 | 28 (71.8) | 11 (28.2) | |
| Missing | 15 | |||
| Histological subtype | 0.278 | |||
| Serous carcinoma | 157 | 97 (61.8) | 60 (38.2) | |
| Mucinous carcinoma | 17 | 14 (82.4) | 3 (17.6) | |
| Endometrioid carcinoma | 19 | 16 (84.2) | 3 (15.8) | |
| Clear-cell carcinoma | 10 | 7 (70.0) | 3 (30.0) | |
| Mixed epithelial tumor | 11 | 9 (81.8) | 2 (18.2) | |
| Undifferentiated tumor | 5 | 3 (60.0) | 2 (40.0) | |
| Unclassified tumor and others | 19 | |||
| FIGO stage | 0.011 | |||
| I+II | 43 | 32 (74.4) | 11 (25.6) | |
| III | 113 | 81 (71.7) | 32 (28.3) | |
| IV | 76 | 41 (53.9) | 35 (46.1) | |
| Not staged or missing | 6 | |||
| Histological differentiation | 0.249 | |||
| High | 19 | 13 (68.4) | 6 (31.6) | |
| Moderate | 61 | 45 (73.8) | 16 (26.2) | |
| Poor | 126 | 79 (62.7) | 47 (37.3) | |
| Not graded or missing | 32 | |||
ZEB1, zinc finger E-box-binding homeobox factor 1; IHC, immunohistochemistry; FIGO, International Federation of Gynecology and Obstetrics.